Department of Ophthalmology, General Hospital of Central Theater Command of PLA (Clinical Medicine Center of Eye Fundus Laser in Hubei Provience), Wuhan, Hubei, China.
Aier Eye Hospital of Wuhan University, 481 Zhongshan Road, Wuhan, 430070, Hubei, China.
BMC Ophthalmol. 2022 Mar 8;22(1):110. doi: 10.1186/s12886-022-02331-z.
To compare the efficacy and safety of subthreshold micropulse (STMP) laser photocoagulation and half-dose photodynamic therapy (PDT) in the treatment of acute central serous chorioretinopathy (CSC).
A total of 39 acute CSC patients were included. 18 patients were treated with STMP laser and 21 patients were treated with half-dose PDT. The main outcome measures were best-corrected visual acuity (BCVA) according to Early Treatment Diabetic Retinopathy Study (ETDRS) chart, the proportion of eyes with complete resolution of subretinal fluid, the number of treatments, and the retinal sensitivity by microperimetry during the 12-month study period.
The mean number of treatments during the 12-month period was 1.6 in STMP group and 1.3 in half-dose PDT group, respectively (P = 0.174). The proportion of eyes with complete resolution of subretinal fluid was 83.3% in STMP group compared with 90.5% in half-dose PDT group at 12-month (P = 0.647). The mean BCVA at 12-month after treatment was 75.28 ± 12.58 for STMP group and 76.62 ± 11.57 for half-dose PDT group, respectively (P = 0.731). No statistically significant difference was found in the mean retinal sensitivity between the two groups during the 12 months follow-up (P = 0.701 at 3 months; P = 0.725 at 6 months; P = 0.695 at 12 months).
Subthreshold micropulse Laser Photocoagulation is as effective as half-dose PDT for acute CSC, while minimizing the damage effect on retinal.
比较阈下微脉冲（STMP）激光光凝和半剂量光动力疗法（PDT）治疗急性中心性浆液性脉络膜视网膜病变（CSC）的疗效和安全性。
共纳入 39 例急性 CSC 患者。18 例患者接受 STMP 激光治疗，21 例患者接受半剂量 PDT 治疗。主要观察指标为根据早期糖尿病视网膜病变研究（ETDRS）图表的最佳矫正视力（BCVA）、视网膜下液完全消退的眼比例、治疗次数以及微视野检查的视网膜敏感度。
STMP 组在 12 个月期间的平均治疗次数为 1.6 次，半剂量 PDT 组为 1.3 次（P=0.174）。STMP 组 12 个月时视网膜下液完全消退的眼比例为 83.3%，半剂量 PDT 组为 90.5%（P=0.647）。治疗后 12 个月时，STMP 组平均 BCVA 为 75.28±12.58，半剂量 PDT 组为 76.62±11.57（P=0.731）。两组在 12 个月的随访中平均视网膜敏感度无统计学差异（3 个月时 P=0.701；6 个月时 P=0.725；12 个月时 P=0.695）。
阈下微脉冲激光光凝治疗急性 CSC 与半剂量 PDT 同样有效，同时最大限度地减少对视网膜的损伤。
